Wednesday, 16 October 2019
Centre of Experimental Rheumatology, University Hospital Zurich
Thursday 17th October 2019
11.30 – 12.30
Kirsten will present:
"Epigenetics of synovial fibroblasts"
Synovial fibroblasts are the most abundant stromal cells in joints that promote inflammation and drive joint destruction in rheumatoid arthritis. Synovial fibroblasts from different joint localizations exhibit profound differences in their expression profiles, which translate into a joint specific enrichment of arthritis relevant pathways, molecules and functional differences. Epigenetic factors act as intermediaries to link genetic and environmental risk factors to altered gene expression levels in a cell type-specific manner. Epigenetic mechanisms define the positional identity of synovial fibroblasts and underlie their role in persistent inflammation. Interfering with epigenetic modifications and their related epigenetic enzymes have therapeutic potential in rheumatoid arthritis.
Professor John Isaacs
Friday, 11 October 2019
The PSORT (Psoriasis Stratification to Optimise Relevant Therapy) Stratified Medicine Consortium will host a one day Showcase event at the Royal College of Physicians, London to highlight its progress, achievements and plans for the future.
Formed by dermatologists, industry partners (including pharmaceutical companies), the British Association of Dermatologists and importantly, the Psoriasis Association, PSORT was established to determine whether it could predict which patients with psoriasis would respond best to a particular biologic drug. This, rather than the existing system of "trial and error" prescribing, would allow new treatment plans to be devised that would be personalised to the individual with psoriasis. If successful, such stratification might also achieve cost savings to the NHS and aid the pharmaceutical industry in the development of new drugs for psoriasis.
The Showcase will focus on how the key aspects of our programme have worked together for patient benefit. It will feature invited lectures by leading international speakers (academic, clinical, industry) interspersed amongst updates from scientists and clinicians from the PSORT team. These will be supplemented by a lunchtime poster exhibition. The day concludes with a networking wine reception.
The Showcase is free to attend and is open to the research community, industry, founders and patients alike.
Join us as we discuss how our findings might be of relevance to you.
To register, please use the BAD registration link https://www.eventsforce.net/bad/277/home
Friday, 27 September 2019
Three international cohorts, two clinical trials including patient reported symptoms, clinical and biological data, proteomics and transcriptomics.
See the latest paper in The Lancet Rheumatology.
Thursday, 26 September 2019
PI Seminar Series
Professor Andy Mellor
Dental Lecture Theatre E
Wednesday 2nd October 2019
13:00 – 14:00
Andy Mellor will present:
"Immunotherapy for chronic diseases: Can we stop the wheels spinning?"
Chronic conditions create huge and growing health care burdens worldwide. Chronic tissue inflammation is a hallmark of many chronic conditions, including cancers, chronic infections, autoimmune cardiovascular and neuro-inflammatory diseases and allergies. Inflammation activates immune cells to incite protective responses against pathogenic organisms. If unresolved, inflammation causes progressive immune dys-function and increased risk of tissue damage and disease. Immune checkpoints discovered in mouse models of cancer offer new insights into the causes and consequences of chronic inflammation and how to manipulate inflammation to modify immune balance for clinical benefit. Our recent work on mouse models of cancer and autoimmune syndromes provides fresh perspectives on how to manipulate the immune system to prevent and treat chronic conditions
Professor Mark Walker
Monday, 16 September 2019
Monday, 5 August 2019
|1.||A two-phase cohort study of the sleep phenotype within primary Sjögren's syndrome and its clinical correlates.|
|Lewis I, Hackett KL, Ng WF, Ellis J, Newton JL.|
|Clin Exp Rheumatol. 2019 Jul 15. [Epub ahead of print]|
|PMID: 31365332 [PubMed - as supplied by publisher]|
|2.||IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function.|
|Ridgley LA, Anderson AE, Maney NJ, Naamane N, Skelton AJ, Lawson CA, Emery P, Isaacs JD, Carmody RJ, Pratt AG.|
|Front Immunol. 2019 Jul 3;10:1535. doi: 10.3389/fimmu.2019.01535. eCollection 2019.|
|PMID: 31333666 [PubMed - in process] Free PMC Article|
|3.||Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.|
|Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.|
|Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.|
|PMID: 31307535 [PubMed - in process] Free PMC Article|
|4.||Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study.|
|Baker KF, Skelton AJ, Lendrem DW, Scadeng A, Thompson B, Pratt AG, Isaacs JD.|
|J Autoimmun. 2019 Jul 4. pii: S0896-8411(19)30196-9. doi: 10.1016/j.jaut.2019.06.009. [Epub ahead of print]|
|PMID: 31280933 [PubMed - as supplied by publisher] Free Article|
Monday, 20 May 2019
Including Nicola Smith on Paediatric Musculoskeletal Care...
ICM Research in Progress Seminar
Monday 20th May
(Dr Venetia Bigley, Prof Matthew Collin, Dr Roman Bauer)
Differential IRF8 requirement defines two pathways of dendritic cell development in vivo
Dendritic cells (DCs) are specialised antigen-processing and presenting cells with critical roles in the regulation of immunity. Human DC subsets develop in the bone marrow under the control of specific transcription factors, mutation of which can result in dendritic cell immunodeficiency in humans. However, how human DCs develop from haematopoietic stem cells is not well mapped.
Single cell transcriptomics, combined with phenotyping and in vitro culture of healthy controls were used to define two distinct pathways of DC development. Their differential requirement for transcription factor IRF8 was interrogated through the analysis of a unique series of patients with IRF8 mutations.
(Prof Helen Foster)
Evaluation of Educational Resources Designed to Facilitate Access to Care for Children with Musculoskeletal Conditions
Children with musculoskeletal diseases have a delay in access to specialist care, with impact on quality of life, development and long term outcomes. If we are to achieve our goal of raising awareness and early recognition of rheumatic disease in childhood through education, we need to understand if, and how, our e-resources lead to change in clinical practice. Our work focuses on developing and piloting an evaluation strategy of the e-resources in real-time, across the stakeholder groups, in order to allow iterative development, optimise uptake and gain insights on impact.
Chair: Henrique De Paula Lemos Dental Lecture Theatre D
1pm - 2pm
Monday, 1 April 2019
Wednesday, 27 March 2019
Monday, 18 March 2019
Registration is now open!
Fatigue: My life, your research
Date: Wednesday 3 April 2019
Venue: Grainger Suite, Life Science Centre, Times Square, Newcastle upon Tyne, NE1 4EP
Time: 11:00-15:00 (Registration from 10:30-11:00)
Refreshments will be provided
NIHR Clinical Research Network North East and North Cumbria is organising an event on Fatigue Research.
We aim to raise awareness of fatigue and explore how it affects many different conditions. In partnership with patients, we will discuss ways to develop new research studies to increase opportunities for patient and public involvement in fatigue research across our region.
The event is free and open to patients, carers, GPs and researchers who have an interest in Fatigue research.
● Learn about current research taking place in fatigue across the region.
● Hear from patients living with fatigue and the impact it has on their lives.
● Share your views and take part in discussions to define what we mean by fatigue.
● Explore how we can develop new research studies in fatigue.
● Discover the support and resources available around the region in our marketplace.
The event is free but please register a place: https://nencfatigue.eventbrite.co.uk
Tuesday, 12 March 2019
Thursday 14th March in L2.4Understanding Biology at omics and structural levelsDr Chichau Miau, Cambridge
Tuesday, 12 February 2019
Marie-Helene Ruchaud-Sparagano from John Simpson's group and Arthur Pratt will discuss their current research (30 minute each).
Monday, 4 February 2019
I have been involved in researching the genetic susceptibility to rheumatoid arthritis (RA) since I joined the Arthritis Research Centre of Excellence, based at the University of Manchester, UK in 1996. Initially focussing on linkage studies using the large collection of family samples collected at the Centre as part of the National Repository, I quickly moved onto genome wide association studies (GWAS), as part of the Wellcome Trust Case Control Consortium (WTCCC), before leading on the fine-mapping of RA loci in the Immunochip study (Nature Genetics, 2012). This study used over 27,000 samples and led to the discovery of 14 new RA susceptibility loci. In recent years my lab has focussed on understanding the mechanisms by which these DNA variants lead to an increase risk of disease. In collaboration with Peter Fraser (Babraham, Cambridge) and Chris Wallace (University of Cambridge), my group has developed methods to interrogate the regions that are associated with RA, mainly regulatory enhancer regions, to determine the interacting gene targets. Using this Capture HiC methodology we are discovering how long range interactions, often involving multiple regions associated with different autoimmune diseases, regulate gene expression. In addition I have established collaborations with Soumya Raychaudhuri (Harvard Medical School, Boston), Caroline Ospelt (Zurich) and David Sansom (UCL), to look at the immunological, epigenetic and non-coding RNA consequences of the RA associated regions. These methods include ChIP, ATAC-Seq, RNA-seq and CRISPR genome editing.
PI Seminar Series
Professor of Immunology and Haemato-oncology Experimental Haematology,
St. James's University Hospital, University of Leeds
Dental Lecture Theatre F
Wednesday 6th February 2019
13:00 – 14:00
Prof Ulf Klein will present:
NF-κB Transcription Factors in B-Cell Lymphomagenesis
Professor Klein has been working on the molecular basis of B-cell development and lymphomagenesis throughout his career. Following his PhD at the University of Cologne, he moved to Columbia University where he was promoted to Associate Professor in 2016. In 2017, he joined the University of Leeds, where he continues his work on elucidating the oncogenic mechanisms that cause malignant transformation of B cells. Currently, a main focus of his lab lies on understanding the roles of the individual NF-κB transcription factor subunits in this process.